A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Lennox-Gastaut syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors INSYS Therapeutics, Inc
  • Most Recent Events

    • 02 Jan 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as the sponsor elected not to continue with study.
    • 01 Dec 2017 Planned initiation date changed from 30 Nov 2017 to 30 Dec 2017.
    • 03 Oct 2017 Planned initiation date changed from 30 Sep 2017 to 30 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top